Hubbry Logo
Viridans streptococciViridans streptococciMain
Open search
Viridans streptococci
Community hub
Viridans streptococci
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Viridans streptococci
Viridans streptococci
Viridans streptococci
View on Wikipedia
from Wikipedia

Viridans streptococci
Scientific classificationEdit this classification
Domain: Bacteria
Kingdom: Bacillati
Phylum: Bacillota
Class: Bacilli
Order: Lactobacillales
Family: Streptococcaceae
Genus: Streptococcus

The viridans streptococci are a large group of commensal streptococcal Gram-positive bacteria species that are α-hemolytic, producing a green coloration on blood agar plates (hence the name "viridans", from Latin "vĭrĭdis", green), although some species in this group are actually γ-hemolytic, meaning they produce no change on blood agar.[1] The pseudo-taxonomic term "Streptococcus viridans" is often used to refer to this group of species, but writers who do not like to use the pseudotaxonomic term (which treats a group of species as if they were one species) prefer the terms viridans streptococci,[2] viridans group streptococci (VGS), or viridans streptococcal species.

These species possess no Lancefield antigens.[3] In general, pathogenicity is low.[4]

Identification

[edit]

Viridans streptococci can be differentiated from Streptococcus pneumoniae using an optochin test, as viridans streptococci are optochin-resistant; they also lack either the polysaccharide-based capsule typical of S. pneumoniae or the Lancefield antigens of the pyogenic members of the genus.[5]

Viridans streptococci Streptococcus pneumoniae
Lysed in bile Insoluble Soluble
Fermentation of inulin Not a fermenter Fermenter with acid production
Sensitivity to optochin Not sensitive Sensitive
Pathogenicity to mice Nonpathogenic Pathogenic
Quellung test (not actively used[citation needed]) Negative Positive

Pathology

[edit]

The organisms are most abundant in the mouth, and one member of the group, S. mutans, is the cause of dental caries in most cases and populations. S. sanguinis is also another potential cause. Others may be involved in other mouth or gingival infections as pericoronitis. If they are introduced into the bloodstream, they have the potential of causing endocarditis, in particular in individuals with damaged heart valves. They are the most common causes of subacute bacterial endocarditis. Viridans streptococci are identified in cases of neonatal infections.[6]

Viridans streptococci have the unique ability to synthesize dextrans from glucose, which allows them to adhere to fibrin-platelet aggregates at damaged heart valves. This mechanism underlies their ability to cause subacute valvular heart disease following their introduction into the bloodstream (e.g., following dental extraction).

Identification

[edit]

The "viridans" group is somewhat of a wastebasket or "grab bag" in streptococci classification. For a review on its identification and taxonomy, refer to Doern and Burnham (2010).[7]

References

[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Viridans streptococci

View on Grokipedia
from Grokipedia
Viridans streptococci, also known as the viridans group streptococci (VGS), are a heterogeneous collection of alpha-hemolytic, Gram-positive, spherical that form chains and are typically part of the normal commensal in the oral cavity, upper , , and . These organisms are named for their characteristic greenish discoloration on blood agar plates due to partial caused by production, distinguishing them from beta-hemolytic streptococci. They are catalase-negative, optochin-resistant, and bile-esculin negative, and lack a polysaccharide capsule, which aids in their identification in clinical labs. Traditionally classified into five major phylogenetic groups—mitis, sanguinis, anginosus, salivarius, and mutans—VGS encompass over 30 recognized species, with Streptococcus mitis, S. sanguinis, S. oralis, S. mutans, and S. salivarius being among the most common. Advances in molecular techniques, such as 16S rRNA sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF), have refined their , moving beyond phenotypic methods that often struggle with species-level differentiation. These exhibit a remarkable ability to form biofilms on surfaces like damaged heart valves, dental enamel, or medical implants, enhancing their adherence and resistance to antibiotics. As opportunistic pathogens, viridans streptococci primarily cause infections when host defenses are compromised or mucosal barriers are breached, such as during dental procedures, in immunocompromised patients, or in those with underlying conditions like or . They are a leading cause of subacute , accounting for 32–43% of cases in pediatric populations (as of the early 2010s), particularly following transient bacteremia from oral trauma. Other notable infections include dental caries and (especially S. mutans), brain or liver abscesses (S. anginosus group), and severe bacteremia in neutropenic children with cancer, where they account for 11–30% of bloodstream infections and carry high mortality risks (up to 19%). Increasing , including to penicillin and , poses challenges in treatment, particularly in pediatric and immunocompromised hosts.

Introduction

Definition and Etymology

Viridans streptococci represent a heterogeneous group of commensal, Gram-positive, alpha-hemolytic or non-hemolytic within the genus . These organisms are characterized by their chain-forming cocci morphology and inability to be classified into Lancefield serogroups, distinguishing them from beta-hemolytic streptococci such as or B species. They typically colonize mucosal surfaces in humans without causing disease under normal conditions but can become opportunistic pathogens. The name "viridans" originates from the Latin word viridis, meaning "," alluding to the distinctive greenish pigmentation observed on blood agar resulting from , where partial breakdown of produces a greenish zone around colonies. This hemolysis pattern, involving oxidation of to , was a key used in early observations. Although the term implies consistent green discoloration, many viridans streptococci exhibit no hemolysis or variable patterns depending on growth conditions. Historically, viridans streptococci were first recognized in the early as oral streptococci producing green hemolysis, with formal efforts beginning around by Andrewes and Horder under the " group." By the , researchers like Sherman refined groupings based on biochemical and hemolytic properties, yet the category evolved into a "wastebasket" or "grab bag" for unclassified streptococci that did not align with more defined pyogenic or enterococcal groups. This informal designation persisted due to their phenotypic diversity until molecular taxonomy in later decades provided clearer delineations.

General Characteristics

Viridans streptococci are Gram-positive cocci typically arranged in pairs or chains, measuring 0.5 to 1.2 μm in diameter. They are facultative anaerobes, non-motile, and non-spore-forming, with older cultures often losing their Gram-positive staining properties. These bacteria grow optimally on enriched media such as blood agar at temperatures between 35°C and 37°C, reflecting their fastidious nature as part of the . The group is characterized by alpha-hemolysis on blood agar, producing a greenish discoloration in the surrounding zone due to the oxidation of to by generated during bacterial metabolism. Some exhibit gamma-hemolysis, showing no visible . Unlike beta-hemolytic streptococci, viridans streptococci do not produce complete . Biochemically, viridans streptococci are catalase-negative and oxidase-negative, aiding in their distinction from other Gram-positive cocci like staphylococci. They lack group-specific Lancefield antigens, are resistant to optochin, and show negative bile solubility. Most are bile-esculin negative and do not possess a capsule, resulting in a negative . These traits underscore their heterogeneity but unify them as a non-pathogenic baseline group. As commensal organisms primarily residing in the oral cavity, viridans streptococci exhibit low inherent pathogenicity in healthy individuals but can act as opportunistic pathogens in immunocompromised hosts or during disruptions to mucosal barriers, leading to infections such as endocarditis or bacteremia.

Taxonomy

Classification

Viridans streptococci are classified within the genus Streptococcus, which occupies a well-defined position in bacterial taxonomy: domain Bacteria; phylum Bacillota (formerly Firmicutes); class Bacilli; order Lactobacillales; family Streptococcaceae. This hierarchy reflects the gram-positive, catalase-negative, chain-forming coccus morphology typical of the genus, with viridans species sharing these core traits while exhibiting diverse phenotypic and genotypic variations. The designation "viridans streptococci" does not constitute a formal taxonomic but serves as an informal phenotypic grouping for alpha-hemolytic and gamma-hemolytic (nonhemolytic) streptococci that are distinct from Streptococcus pneumoniae and the beta-hemolytic pyogenic groups (such as groups A, B, C, and G streptococci). This classification arose from early observations of their partial or absent on blood , producing a greenish (viridis) tint, and excludes enterococci and other non-streptococcal genera. Phylogenetically, viridans streptococci are integrated into the broader Streptococcus phylogeny, particularly within the Mitis group and related subgroups like the anginosus and salivarius complexes. Major taxonomic revisions began in the 1980s with the advent of 16S rRNA gene sequencing, which revealed high interspecies homology (often >99%) and prompted reclassifications of former "viridans" strains into distinct species; subsequent multilocus sequence analysis (MLSA) of housekeeping genes has further refined these boundaries by resolving genetic exchanges and improving species delineation. The viridans group remains a heterogeneous assemblage, often described as a "" for streptococcal species that do not align neatly with pyogenic, bovis, or mutans groups, resulting in persistent challenges and ongoing reclassifications driven by genomic data. This fluidity underscores the limitations of early phenotypic methods and the value of molecular approaches in stabilizing .

Major Groups and Species

Viridans group streptococci (VGS) are taxonomically organized into five major phylogenetic groups based on 16S rRNA sequencing and multilocus , reflecting their within the genus. These groups encompass over 30 recognized species, primarily associated with human hosts, including key examples such as Streptococcus parasanguinis and Streptococcus cristatus. The Anginosus group includes species like S. anginosus, S. constellatus, and S. intermedius, which are notable for their role in human microbiota. The Mitis group comprises common oral commensals such as S. mitis and S. oralis. The Sanguinis group features species including S. sanguinis and S. gordonii, known for interactions with host cells. The Salivarius group consists of S. salivarius and S. vestibularis, predominant in oral and pharyngeal environments. Finally, the Mutans group contains S. mutans and S. sobrinus, significant in dental contexts. The classification of VGS has evolved from early phenotypic methods, which relied on biochemical tests and morphology, to genotypic approaches. DNA-DNA hybridization studies in the late 20th century provided more precise species delineation, as demonstrated in taxonomic revisions of oral streptococci. More recently, whole-genome sequencing has refined phylogenetic relationships, enabling comprehensive analysis of over 60 streptococcal genomes and confirming the five-group structure.

Ecology

Habitat

Viridans streptococci primarily inhabit the human oral cavity, where they colonize dental plaque, saliva, the tongue, and other mucosal surfaces as commensal bacteria. They are also present in the upper respiratory tract, gastrointestinal tract, and female genital tract, though at lower densities compared to the oral environment. In the oral cavity, these bacteria serve as early colonizers of tooth surfaces, forming biofilms that constitute a significant portion of the supragingival plaque biomass, often comprising 60% to 90% during initial colonization phases. Their dominance as human commensals is evident in the oral biofilms, where they account for, for example, 28% of the cultivable microflora in supragingival plaque and 46% in in adults. Distribution within these habitats is influenced by their aciduric properties, allowing tolerance of low environments in the (such as those below 5.5 created by dietary sugars), particularly in species like those in the mutans group. Adherence to mucosal surfaces and teeth is facilitated by surface structures including pili and adhesins, such as the antigen I/II family proteins, which bind to salivary components and host . In non-human hosts, viridans streptococci are detected in the oral cavities of some animals, including like chimpanzees, gorillas, and baboons, where they exhibit site-specific similar to humans but with varying abundances. Human-specific adaptations predominate, with lower prevalence in more distant hosts like , underscoring their primary association with oral ecosystems.

Role in Normal Flora

Viridans streptococci serve as key commensal within the human oral microbiota, constituting a significant portion of the microbial in and . In adults, streptococci, predominantly from the viridans group, account for 28% of cultivable in supragingival plaque and 46% in , where they act as early colonizers that initiate formation on surfaces. By adhering to the salivary pellicle via adhesins such as I/II proteins, these establish structured multispecies that provide a stable niche for other commensals while limiting space for opportunistic invaders. This architecture enhances overall microbial in the oral cavity. Ecologically, viridans streptococci contribute to a balanced oral environment through competitive interactions and metabolic activities. They compete with potential pathogens for nutrients and adhesion sites, producing antimicrobial agents like (up to 1.4 mM) and to suppress harmful species such as . Additionally, certain viridans species utilize the arginine deiminase system to generate , thereby elevating plaque pH and counteracting acid-induced demineralization. Their antigens further modulate host immunity by downregulating pro-inflammatory pathways like and inducing such as human β-defensin 2, fostering tolerance and reducing excessive inflammation. These mechanisms collectively promote colonization resistance against exogenous microbes. Colonization by viridans streptococci begins shortly after birth, often through from maternal oral flora, with streptococci comprising over 90% of the infant oral microflora within the first 48 hours. In healthy individuals, this community stabilizes during adulthood but can shift in response to factors such as aging, dietary changes, or variations in practices, altering species proportions and composition. For instance, improved may reduce overall bacterial load, while diet influences availability for streptococcal . In immunocompetent hosts, viridans streptococci remain generally avirulent, functioning as neutral residents that maintain ecological balance without causing harm. They serve as a within the oral cavity, from which can occasionally translocate to other sites under specific conditions, though this rarely leads to pathology in healthy individuals.

Mechanisms

Viridans streptococci employ several mechanisms that facilitate their transition from commensal organisms to opportunistic pathogens, primarily through enhanced , immune modulation, enzymatic degradation, and exploitation of host vulnerabilities. to host tissues and medical devices is mediated by surface adhesins such as fibronectin-binding proteins and sialic acid-binding proteins like Hsa in species such as , which promote initial attachment to endothelial cells. Additionally, type IV pili in S. sanguinis contribute to adherence and initiation on host surfaces. formation is bolstered by the production of extracellular , including dextrans synthesized via glucosyltransferases in S. mutans, which provide structural stability and protect against shear forces and antimicrobials. These , often involving exopolysaccharides (EPS), enable persistent and evasion of host defenses by embedding bacteria within a protective matrix. Immune evasion strategies in viridans streptococci include the production of (H₂O₂), which inhibits phagocytic activity of neutrophils and competes with other oral microbes, as observed in species like S. sanguinis and S. gordonii. Some strains possess capsule-like structures that inhibit by polymorphonuclear neutrophils, reducing opsonization and clearance. Biofilms formed by these streptococci also contribute to immune detection avoidance by limiting exposure to circulating antibodies and complement proteins. Virulence is enhanced by the secretion of enzymes and toxins that promote tissue invasion and host cell damage. , produced by species such as S. intermedius, degrades in extracellular matrices, facilitating bacterial spread through tissues. activity is widespread among viridans group streptococci, cleaving residues from host glycoconjugates to expose receptors for adhesion and disrupt mucosal barriers. In S. sanguinis, platelet-activating factors like the serine-rich repeat SrpA bind to and activate platelets, promoting aggregation and formation on damaged . The opportunistic nature of viridans streptococci relies on their ability to translocate from oral niches into the bloodstream during transient bacteremia, often triggered by dental procedures or mucosal disruption. Once disseminated, they exploit compromised host sites, such as damaged heart valves or atherosclerotic plaques, where endothelial injury exposes subendothelial for adherence. This is particularly pronounced in immunocompromised individuals, where reduced innate immunity allows proliferation at distant sites.

Associated Diseases

Viridans streptococci are implicated in various oral and dental infections, primarily due to their role as commensal flora in the oral cavity that can become pathogenic under certain conditions. is a key etiological agent in dental caries, where it contributes to formation and acid production leading to enamel demineralization. Other , such as S. sanguinis and S. oralis, are associated with through their involvement in supragingival plaque accumulation and early inflammatory responses in the gingival crevice. The S. anginosus group, including S. anginosus and S. intermedius, is frequently isolated from and dental abscesses, where they promote purulent infections around partially erupted third molars or apical regions. Systemically, viridans streptococci are a leading cause of , particularly involving S. sanguinis and S. mitis, which adhere to damaged heart valves forming vegetations; this association is often linked to transient bacteremia from oral sources. They also cause bacteremia, especially following dental procedures, and septicemia in neutropenic patients, where S. mitis predominates and can lead to high mortality rates. In these cases, the bacteria's ability to form biofilms on endothelial surfaces exacerbates the infection. Additional infections include in immunocompromised individuals, often involving the S. anginosus group. The S. anginosus group is notably associated with abscesses, where S. intermedius contributes to suppurative intracranial lesions. Urinary tract infections are less common but reported with species like S. acidominimus in vulnerable populations. Historically, viridans streptococci were a major cause of infective endocarditis before the antibiotic era, with Hugo Schottmüller first isolating them from subacute cases in 1910 and Emanuel Libman confirming their prevalence in 35 of 36 patients studied; poor dental health was recognized as a key entry portal for bacteremia leading to valvular infections.

Clinical Features

Infections and Complications

Viridans streptococci are a common cause of subacute infective endocarditis, characterized by an insidious onset with low-grade fever exceeding 38.0°C in over 95% of cases, accompanied by fatigue, malaise, and chills. A new or worsening heart murmur may develop in fewer than 50% of patients, often reflecting valvular involvement, particularly of the mitral or aortic valves. Complications arise in a significant proportion of cases, including systemic emboli causing neurologic deficits in 15% to 30% of patients, congestive heart failure due to acute valvular regurgitation in approximately 33%, and progressive valve destruction from perforation or chordae tendineae rupture. In dental infections, viridans streptococci commonly present with localized pain and swelling in the affected area, such as the face or , often with formation manifesting as suppurative discharge from dental roots or fistulas. and involvement, like , can occur as the infection spreads through soft tissues. Untreated, these infections may progress rapidly to deep-seated abscesses involving multiple facial spaces, potentially leading to with airway compromise or disseminated , including and distant sites like the or . Bacteremia due to viridans streptococci frequently manifests as transient episodes following dental procedures or mucosal disruptions, typically resolving without intervention but occasionally persisting in immunocompromised hosts. In patients with hematologic malignancies or , persistent bacteremia can lead to severe complications in about 13% of cases, including and , with a attributable mortality of around 2%. The viridans streptococcal shock syndrome, a toxic shock-like state, is a notable in these settings, marked by and multiorgan failure. Neonatal infections by viridans streptococci often present as early-onset within the first 72 hours of life, accounting for over half of cases in affected infants, with symptoms including respiratory distress and hemodynamic instability. is a frequent manifestation, seen in nearly 28% of pediatric cases, contributing to an overall mortality rate of 12.3%, particularly high in cases involving . occurs in a subset, typically as hospital-acquired or presumed based on bacteremia with pleocytosis, leading to rapid deterioration and potential fatality in vulnerable neonates. Long-term complications of viridans streptococci infections include the emergence of antibiotic resistance, with rates of penicillin non-susceptibility reaching 29% and non-susceptibility of 8% in bacteremic isolates from a 2024 study in , complicating therapy in recurrent cases. In at-risk groups such as those with hematologic disorders, recurrent bacteremia episodes are common, driven by ongoing , and can result in chronic sequelae like persistent organ damage from prior shock or emboli.

Risk Factors

Viridans streptococci infections, particularly bacteremia and , are more likely in individuals with underlying host factors that compromise immune defenses or provide sites for bacterial adhesion. from conditions such as for malignancies or infection significantly elevates susceptibility, as these states impair function and mucosal barriers, facilitating translocation of oral flora into the stream. Patients with prosthetic heart valves or congenital heart disease face heightened risk due to endothelial damage and turbulent flow, which promote bacterial and vegetation formation on cardiac structures. Diabetes mellitus further contributes by altering immune responses and promoting gingival inflammation, increasing the likelihood of oral bacteremia. Procedural interventions that disrupt or introduce directly into the circulation also serve as key risk factors. Dental extractions and other invasive oral procedures can cause transient bacteremia in up to 50% of cases without prophylaxis, allowing viridans streptococci to enter the bloodstream and seed distant sites in susceptible hosts. Intravenous use heightens by enabling introduction of oral contaminants through shared or contaminated , though it more commonly involves ; poor injection hygiene exacerbates this for oral streptococci. Surgical procedures lacking appropriate prophylaxis similarly pose risks, especially in patients with cardiac abnormalities. Certain demographic groups exhibit increased incidence due to age-related or lifestyle-associated vulnerabilities. Neonates and the elderly are particularly prone, with neonates at risk from immature immunity and nosocomial exposure, and older adults from comorbidities and reduced salivary flow impairing oral clearance. Alcoholics face elevated susceptibility owing to impaired and frequent aspiration of oral contents, compounded by poor and . Poor across demographics promotes chronic and periodontitis, serving as a portal for bacteremia entry during routine activities like toothbrushing, which induces transient viridans streptococci bacteremia in 20-50% of individuals. Epidemiologically, infections occur at higher rates in developing regions where access to dental care is limited, leading to untreated oral diseases and increased bacteremia episodes from daily activities. This disparity underscores the role of socioeconomic factors in amplifying procedural and hygiene-related risks globally.

Diagnosis

Microbiological Identification

Viridans streptococci are isolated from clinical specimens through culture on enriched media such as blood agar, where they typically exhibit alpha-hemolysis, resulting in greenish discoloration around the colonies due to partial hemolysis of red blood cells. Colonies are usually pinpoint to small in size and become visible after 24 to 48 hours of incubation at 35–37°C in an atmosphere of 5% CO₂. These organisms appear as Gram-positive cocci in chains and are catalase-negative, distinguishing them from staphylococci. Phenotypic identification relies on several biochemical tests to confirm the group and differentiate from closely related streptococci. Viridans streptococci are resistant to optochin, showing no zone of inhibition around an optochin disk (≥6 mm), unlike the sensitive . They are also bile solubility-negative, failing to lyse in 2–10% bile salts, further separating them from pneumococci. The is negative, as these organisms do not produce the arrowhead-shaped in proximity to on blood agar, a reaction typical of streptococci. patterns assessed via carbohydrate utilization tests reveal variability; for instance, most viridans species do not ferment inulin, in contrast to pneumococci which produce acid from it. Differentiation from other streptococci involves additional tests targeting and enzymatic activity. Unlike beta-hemolytic streptococci (e.g., groups A, B, C, G), viridans streptococci do not produce complete on blood agar. They are distinguished from enterococci by being bile-esculin negative, showing no blackening on bile-esculin agar, and lacking growth in 6.5% NaCl broth. The PYR (pyrrolidonyl arylamidase) test yields variable results, with approximately 82% of viridans streptococci testing negative, though some species may be positive, limiting its utility for definitive identification. As a heterogeneous group comprising over 10 , viridans streptococci pose challenges for precise phenotypic due to overlapping biochemical profiles and inconsistent reactions in traditional tests. Accurate species-level identification often requires commercial identification kits such as API 20 Strep or VITEK systems, which combine multiple enzymatic and fermentation assays, though even these may misidentify isolates without supplementary methods.

Molecular Methods

Molecular methods have revolutionized the identification of viridans streptococci by providing genotypic precision that addresses the limitations of phenotypic approaches, particularly given the group's taxonomic heterogeneity. Polymerase chain reaction (PCR)-based techniques, such as 16S rRNA gene sequencing, serve as a gold standard for genus-level confirmation, achieving ≥99% similarity thresholds for species identification according to Clinical and Laboratory Standards Institute (CLSI) guidelines. This method correctly identifies the majority of clinical isolates to the species level, outperforming conventional phenotypic tests. For more refined species differentiation, multilocus sequence typing (MLST) targets seven housekeeping genes—accA, gki, hom, oppC, patB, rlmN, and tsf—to characterize population diversity and distinguish subgroups like Streptococcus mitis from closely related taxa. For example, in S. mitis, MLST resolved 259 sequence types across 322 genomes, enabling standardized typing via public databases like PubMLST. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) offers rapid proteomic profiling for both group and species identification, increasingly adopted as a standard in clinical laboratories due to its speed and cost-effectiveness. Systems like Biotyper achieve 100% genus-level correlation with reference sequencing methods such as rpoB, with species-level accuracy varying for challenging subgroups like the Mitis group after database updates. VITEK MS () similarly provides high group-level identification but may struggle with fine discrimination between closely related species like S. mitis and S. oralis. These platforms surpass traditional biochemical tests and are recommended for routine use in verifying viridans streptococci isolates, particularly in bloodstream infections. As of 2025, updated Biotyper databases have further improved accuracy in distinguishing VGS from S. pneumoniae. Whole-genome sequencing (WGS) extends these capabilities for comprehensive analysis, facilitating outbreak investigations, detection of genes, and precise subgroup delineation such as mitis versus mutans. In clinical contexts like , WGS using platforms like Illumina MiSeq has identified 88% of streptococcal strains as viridans or bovis groups (primarily mitis and bovis groups; note bovis is taxonomically distinct from VGS). It provides superior resolution for subspecies affiliation through core genome phylogeny, enabling unambiguous strain typing beyond partial targets. These molecular approaches collectively overcome phenotypic ambiguities inherent in viridans streptococci, detect unculturable or low-abundance strains via metagenomic extensions, and support speciation as emphasized in clinical guidelines advocating MALDI-TOF verification. By integrating with phenotypic methods, they enhance diagnostic accuracy in complex infections, prioritizing high-impact applications like resistance profiling over exhaustive routine screening. EUCAST revised susceptibility breakpoints for viridans streptococci in 2024 to improve testing interpretation.

Treatment

Antimicrobial Therapy

Viridans group streptococci (VGS) exhibit high susceptibility to beta-lactam antibiotics, with most isolates showing minimum inhibitory concentrations (MICs) for penicillin G of ≤0.12 μg/mL, though rates of nonsusceptibility vary by species and clinical context, reaching 14-29% in recent U.S. surveillance data. and demonstrate even broader activity, with susceptibility rates exceeding 96% and 99%, respectively, across VGS species. Emerging resistance to penicillin has been noted in oral isolates, with nonsusceptibility rates of 5-30% reported in diverse populations, particularly among group organisms. For caused by highly penicillin-susceptible VGS (MIC ≤0.12 μg/mL), the recommends aqueous crystalline penicillin G at 12-18 million units intravenously per 24 hours, administered continuously or in 4-6 divided doses for 4 weeks, or 2 g intravenously or intramuscularly once daily for 4 weeks. In native endocarditis with uncomplicated cases, a shorter 2-week regimen of penicillin G or combined with gentamicin (3 mg/kg per 24 hours intravenously or intramuscularly in one dose) provides effective bactericidal synergy. For relatively resistant strains (MIC >0.12 to ≤0.5 μg/mL), the 4-week beta-lactam course is extended with gentamicin for the initial 2 weeks to enhance efficacy. Penicillin-allergic patients should receive 15 mg/kg intravenously every 12 hours, adjusted to achieve trough levels of 15-20 μg/mL, for 4 weeks. Treatment of non-endocarditis VGS infections, such as bacteremia or dental abscesses, typically involves oral amoxicillin 500 mg every 8 hours for 7-14 days in susceptible cases, reflecting its activity against penicillin-susceptible oral flora. For penicillin-allergic or resistant strains in these settings, or serves as an alternative, with durations tailored to severity. Beta-lactamase production is rare among VGS, with resistance primarily arising from altered rather than enzymatic inactivation. However, high-level resistance to aminoglycosides, mediated by modifying enzymes, occurs in up to 20% of isolates and can impair synergistic combinations in serious infections like . Susceptibility testing is essential for all VGS isolates from sterile sites to guide therapy, given variable resistance patterns across species.

Prophylaxis

Prophylaxis against viridans group streptococcal infections primarily targets the prevention of (IE), the most significant clinical concern associated with transient bacteremia from these oral commensals, particularly in patients with underlying cardiac conditions. The (AHA) guidelines, updated in 2021 without substantive changes from the 2007 revision, recommend prophylaxis exclusively for a narrow of highest-risk patients undergoing specific dental procedures, reflecting a shift away from broader application due to the rarity of IE attributable to viridans group streptococci (VGS) and concerns over antibiotic overuse. These high-risk groups include individuals with prosthetic cardiac valves or prosthetic material used for cardiac valve repair, a history of IE, unrepaired cyanotic congenital heart disease (CHD) or repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device, and cardiac transplant recipients who develop cardiac valvulopathy. Antibiotic prophylaxis is indicated only for dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the , as these are associated with the highest risk of VGS bacteremia. The standard regimen consists of a single oral dose of (2 g for adults; 50 mg/kg, up to 2 g, for children) administered 30 to 60 minutes before the procedure. For patients unable to take oral medications, alternatives include or intravenously or intramuscularly (2 g for adults; 50 mg/kg for children). In cases of penicillin allergy, acceptable options are cephalexin (2 g oral for adults), or (500 mg oral for adults), or // parenterally; clindamycin is no longer recommended due to emerging resistance patterns among viridans streptococci. Prophylaxis is not recommended for gastrointestinal or genitourinary procedures, even in high-risk patients, as the bacteremia risk from VGS in these contexts is negligible compared to oral sources. The evolution of these guidelines since the has progressively restricted prophylaxis indications, driven by epidemiological data showing that only an exceedingly small fraction of VGS IE cases (estimated at fewer than 1 in 100,000 procedures in at-risk patients) can be prevented through antibiotics, balanced against risks such as and adverse effects. Earlier protocols, such as those from the 1997 AHA update, included moderate-risk patients like those with , but the 2007 revision eliminated these to focus solely on highest-risk categories, a stance reaffirmed in after review of incidence data indicating no increase in IE rates post-restriction. Non-antibiotic preventive strategies emphasize maintaining optimal oral health to minimize everyday bacteremia from viridans streptococci, which occurs more frequently from routine activities like toothbrushing in patients with poor hygiene than from isolated procedures. Regular dental care, including biannual professional cleanings and daily oral hygiene practices such as brushing and flossing, is strongly recommended for all at-risk patients to reduce gingival inflammation and plaque accumulation, thereby lowering VGS translocation into the bloodstream. Chlorhexidine gluconate rinses (0.12%) have shown efficacy in reducing post-procedure VGS bacteremia in some studies but are not endorsed as routine prophylaxis by major guidelines due to limited long-term evidence and potential for resistance. In high-risk non-cardiac groups, such as patients undergoing or , prophylaxis strategies incorporate enhanced oral care protocols alongside targeted antibiotics. For individuals at intermediate-to-high risk of infection (e.g., those with profound neutropenia lasting >7 days), the Infectious Diseases Society of America (IDSA) recommends fluoroquinolone-based antibacterial prophylaxis (e.g., levofloxacin 500 mg daily), which provides coverage against viridans streptococci, though breakthrough VGS bacteremia can occur due to resistance. Adjunctive measures include oral rinses combined with standard hygiene to mitigate mucositis-related VGS entry, particularly in patients. No licensed vaccines exist for VGS IE prevention, though experimental approaches targeting adhesins like FimA have demonstrated protection in animal models, with ongoing immunoinformatics research exploring multi-epitope constructs.

References

  1. https://www.osmosis.org/learn/Streptococcus_viridans
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3020876/
  3. https://step1.medbullets.com/microbiology/104029/viridans-group-streptococci
  4. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540525/all/Streptococcus_species
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC10917554/
  6. https://www.merckmanuals.com/professional/infectious-diseases/gram-positive-cocci/streptococcal-infections
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6287261/
  8. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.1025136/full
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC358123/
  10. https://www.ncbi.nlm.nih.gov/books/NBK7611/
  11. https://science.umd.edu/classroom/bsci424/pathogendescriptions/Streptococcus.htm
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7729260/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC126867/
  14. https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=1313
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8942026/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC2546745/
  17. https://journals.asm.org/doi/10.1128/jcm.42.6.2651-2657.2004
  18. https://sajid.co.za/index.php/sajid/article/view/563/1474
  19. https://microbiologyjournal.org/a-review-on-updated-species-list-of-viridans-streptococci-causing-infective-endocarditis/
  20. https://www.microbiologyresearch.org/content/journal/micro/10.1099/00221287-135-10-2623
  21. https://f1000research.com/articles/2-67
  22. https://journals.asm.org/doi/10.1128/AEM.02066-10
  23. https://academic.oup.com/cid/article-pdf/34/11/1524/1052438/34-11-1524.pdf
  24. https://pdfs.semanticscholar.org/8a44/32c4512a40f4f0d153dd2dad556507b97e65.pdf
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC2738137/
  26. https://www.nature.com/articles/s41522-024-00642-1
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC9664950/
  28. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1357631/full
  29. https://doi.org/10.15197/ejgm.1440
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC10067990/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC153257/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC8579931/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC1111834/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC6770522/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC7221147/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC12533616/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC267946/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC5388602/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC8748486/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7761167/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC6491369/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC308963/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC5453655/
  44. https://www.ncbi.nlm.nih.gov/books/NBK557641/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC7492120/
  46. https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-13-273
  47. https://journals.asm.org/doi/10.1128/jcm.01563-10
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC11079360/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC3918336/
  50. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000969
  51. https://www.ncbi.nlm.nih.gov/books/NBK579762/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3734757/
  53. https://www.sciencedirect.com/topics/medicine-and-dentistry/viridans-streptococci
  54. https://academic.oup.com/jac/article/79/9/2327/7708977
  55. https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-019-0341-x
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC104706/
  57. https://microbiologyinfo.com/pyr-test-principle-uses-procedure-and-result-interpretation/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC9879099/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC12039398/
  60. https://esmed.org/MRA/mra/article/view/3037
  61. https://www.eucast.org/news-detail/comments-and-responses-to-the-consultation-on-pneumococci-and-viridans-streptococci/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC9117386/
  63. https://journals.asm.org/doi/10.1128/spectrum.00160-23
  64. https://pubmed.ncbi.nlm.nih.gov/3644853/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC3681201/
  66. https://pubmed.ncbi.nlm.nih.gov/24610586/
  67. https://www.nice.org.uk/guidance/cg64/evidence/full-guideline-pdf-196759981
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC3110859/
  69. https://www.med.unc.edu/pediatrics/cccp/wp-content/uploads/sites/1156/2025/06/Peds-HOPPx-Guideline_03.20241.pdf
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC127623/
  71. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1524128/full
Add your contribution
Related Hubs
User Avatar
No comments yet.